Last reviewed · How we verify
Topical 2,5% lidocaine + 2,5% prilocaine gel
Topical 2,5% lidocaine + 2,5% prilocaine gel is a Local anesthetic Small molecule drug developed by Pontificia Universidad Catolica de Chile. It is currently in Phase 3 development for Topical treatment of pain associated with minor cuts, scrapes, and burns.
Lidocaine and prilocaine work by blocking the action of sodium channels in nerve cells, preventing the transmission of pain signals.
Lidocaine and prilocaine work by blocking the action of sodium channels in nerve cells, preventing the transmission of pain signals. Used for Topical treatment of pain associated with minor cuts, scrapes, and burns.
At a glance
| Generic name | Topical 2,5% lidocaine + 2,5% prilocaine gel |
|---|---|
| Sponsor | Pontificia Universidad Catolica de Chile |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
This results in a temporary numbing effect, reducing pain and discomfort in the affected area. The combination of lidocaine and prilocaine allows for a synergistic effect, increasing the duration and intensity of the numbing effect.
Approved indications
- Topical treatment of pain associated with minor cuts, scrapes, and burns
Common side effects
- Skin irritation
Key clinical trials
- Hyaluronic Acid vs Botulinum Toxin Injection in Treatment of Lifelong Drug-Resistant Premature Ejaculation: Randomized Study (NA)
- Local Anesthesia Before Bulkamid Injection (NA)
- A Comparative Study of Selective Dorsal Neurectomy, Pulsed Radiofrequency Neuromodulation, and Intragranular Hyaluronic Acid Injection for Premature Ejaculation (NA)
- Enhanced Provision of Male Circumcision (MC) for HIV Prevention, Rakai, Uganda (PHASE2, PHASE3)
- Topical Formulations of Liposomal Local Anesthetics (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical 2,5% lidocaine + 2,5% prilocaine gel CI brief — competitive landscape report
- Topical 2,5% lidocaine + 2,5% prilocaine gel updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI
Frequently asked questions about Topical 2,5% lidocaine + 2,5% prilocaine gel
What is Topical 2,5% lidocaine + 2,5% prilocaine gel?
How does Topical 2,5% lidocaine + 2,5% prilocaine gel work?
What is Topical 2,5% lidocaine + 2,5% prilocaine gel used for?
Who makes Topical 2,5% lidocaine + 2,5% prilocaine gel?
What drug class is Topical 2,5% lidocaine + 2,5% prilocaine gel in?
What development phase is Topical 2,5% lidocaine + 2,5% prilocaine gel in?
What are the side effects of Topical 2,5% lidocaine + 2,5% prilocaine gel?
What does Topical 2,5% lidocaine + 2,5% prilocaine gel target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: Pontificia Universidad Catolica de Chile — full pipeline
- Therapeutic area: All drugs in Pain management
- Indication: Drugs for Topical treatment of pain associated with minor cuts, scrapes, and burns
- Compare: Topical 2,5% lidocaine + 2,5% prilocaine gel vs similar drugs
- Pricing: Topical 2,5% lidocaine + 2,5% prilocaine gel cost, discount & access